Abstract
Background Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.
Objective This study aims to supplement the surveillance data provided by the CDC by describing the latest trends (through January 31, 2024) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).
Methods Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provide more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2019 and February 04, 2024. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.
Results We included 491,342 hospitalizations of 456,820 unique patients who tested positive for a respiratory virus between October 01, 2019 and February 04, 2024. Overall, the rate of hospitalizations associated with respiratory viruses has decreased throughout January 2024 (−35.3%) compared to December 2023. The largest decreases were seen in parainfluenza virus- (−49.0%), RSV- (−48.0%), and influenza-associated (− 41.6%) hospitalizations. For infants and children, rhinovirus-associated hospitalizations were the only virus to increase over the last month and now accounts for the largest percentage of hospitalizations in this population (even greater than RSV-associated hospitalizations). The population over 65 years of age also saw a decrease in respiratory virus-associated hospitalizations (−39.4%). COVID remained the largest contributor; 3.75% of all hospitalizations were associated with COVID in the older adult population.
Discussion We continue to see evidence that respiratory virus-associated hospitalizations peaked at end of 2023 and continue to decrease overall, including for the two high-risk populations we studied. In January 2024, rhinovirus-associated hospitalizations were the main respiratory virus contributing to hospitalizations for infants and children, while COVID-associated hospitalizations were the largest contributor for the older adult population. We will continue to monitor trends in all respiratory viruses.
Overall populationOverall, the rate of hospitalizations associated with respiratory viruses decreased throughout January 2024 (35.3% decrease since beginning of January 2024). Specifically, parainfluenza virus- (−49.0%), RSV- (−48.2%), and influenza-associated (− 41.6%) hospitalizations have all decreased throughout the month. COVID- and influenza-associated hospitalizations make up 2.5% and 2.7% of all hospitalizations, respectively. Other respiratory viruses studied each make up less than 1% of hospitalizations. Nevertheless, in the last week of January 2024, respiratory virus-associated hospitalizations accounted for 5.3% of all hospitalizations.
Infants and children (age 0-4)For the population between 0-4 years old, respiratory virus-associated hospitalizations decreased throughout January (−28.0%). Hospitalizations associated with all viruses decreased with the exception of rhinovirus, which has increased overall since the beginning of January, and experienced the largest increase in the last two weeks of the month (22.3% increase since the beginning of January). In this age group, 4.1% of all hospitalizations were associated with respiratory viruses in January 2024, a 28.0% decrease from the first week of January 2024.
Older adults (age 65 and over)In the population over 65 years of age, there was a 39.4% decrease in hospitalizations associated with respiratory viruses. All respiratory viruses studied continued to decrease throughout the month, with the exception of HPMV-associated hospitalizations, which had a small increase of 5.1% compared to the beginning of the month. COVID-associated hospitalizations continue to make up the largest percentage of hospitalizations in this age group (3.8% in January 2024). In the last week of January 6.6% of all hospitalizations in this age group were associated with a respiratory virus.
Competing Interest Statement
All authors are employees of Truveta, Inc
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Normalized electronic health record data are de-identified by expert determination under the HIPAA Privacy Rule before being made available to researchers. In accordance with 46.101 Protection of Human Subjects, our study did not require Institutional Review Board approval because it used only deidentified medical records. All data used in this study are publicly available to Truveta subscribers and may be accessed at studio.truveta.com.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This revision includes now data till January 2024.
Data Availability
The data used in this study are available to all Truveta subscribers and may be accessed at studio.truveta.com.